Skip to main content

Table 1 List of Antiangiogenic Drugs Approved for Clinical Use

From: The inefficacy of antiangiogenic therapies

Drug

Target

Company

Indication

Avastin

(Bevacizumab)

VEGF

Genentech

mCRC, NSCLC, Advanced breast cancer

Erbitux

(Cetuximab)

EGFR

Imclone

mCRC & Head and Neck cancer

Vectibix

(Panitumumab)

EGFR

Amgen

mCRC

Lucentis

(Ranibizumab)

VEGF

Genentech

Wet Age-related macular regeneration

Macugen

(Pegaptanib)

VEGF

OSI Pharmaceuticals

Wet Age-related macular regeneration

Endostar

(Endostatin)

Angiogenesis inhibitor

Shangdong Simcere Medgen

Lung cancer

Sorafenib

(Nexavar)

VEGFR, PDGFR &

Raf

Bayer AG/Onyx

Advanced RCC

Sunitinib

(Sutent)

VEGFR, PDGFR &

c-kit

Pfizer

Advanced RCC & GIST

Thalomid

(Thalidomide)

Angiogenesis inhibitor

Celgene Corporation

Multiple Myeloma

Sorafenib

(Nexavar)

VEGFR, PDGFR &

c-kit

Bayer AG/Onyx

Advanced RCC

Sunitinib

(Sutent)

PDGFR & VEGFR

Pfizer

Advanced RCC & GIST

Dasatinib

(Sprycel)

Bcr-Abl & Src

Bristol-Myers Squibb

Gleevec-resistant CML or Ph+ ALL

Lapatinib

(Tykerb)

EGFR & Her2/neu

GlaxoSmithKline

Advanced metastatic Her2+ breast cancer

Velcade

(Bortezomib)

Proteosome inhibitor

Millenium Pharmaceuticals

Multiple myeloma

Tarceva

(Erlotinib)

EGFR

Genentech/OSI

Lung cancer